We expand, promote, facilitate multidisciplinary activities in HIV/AIDS research

HU CFAR HOME | CORE SERVICES | RESEARCH PRIORITIES

IN THIS NEWSLETTER:

Updates
CFAR Events
Publications Highlights
Recent Funding Opportunities

UPDATES

Led by Abigail Batchelder, PhD, MPH and Peter Chai, MD, MMS the Harvard University Center for AIDS Research is excited to announce the launch of the Substance Use & HIV Scientific Working Group, the purpose of which is to facilitate innovative and fruitful collaborations focused on substance use and HIV across Harvard University and its affiliated institutions. To learn more about the Substance Use & HIV Scientific Working Group, click here. To inform the scope of this scientific working group we invite those in this field of research, and those interested in it, to complete this brief survey.

CONGRATULATIONS TO OUR AUGUST 2021 AWARDEES!

Developmental Awardees:

Yannic Bartsch, PhD (MGH) "Antibody glycosylation as marker and mechanism of spontaneous HIV control"

Ciputra Hartana, MD, PhD (MGH) "Trained Immunity in HIV-1 elite controllers"

Jana Jarolimova, MD, MPH (MGH) "Implementing a rapid test for gonorrhea and chlamydia among adults at risk for HIV"

Maria Nardell, MD (BWH) "The impact of internal migration on men's engagement in HIV care in South Africa"

Supplement Awardees

Parmit Singh, PhD (DFCI) "Role of splicing-dependent Pol II pausing in the formation of latent HIV-1 reservoirs"

Amir Mohareb, MD (MGH) "Addressing the burden of HIV-hepatitis B in commercial sex workers in sub-Saharan Africa"
Adedotun Ogunbajo, PhD, MPH, MHS (HSPH) "Intersectional stigma & HIV care outcomes among sexual minority men in Nigeria"

Daniel Escudero, PhD, MPH (HSPH) "Improving Routine Opt-out HIV Screening in the Emergency Department in Miami, Florida"

The NIH has awarded a total of $53 million to 10 institutions for HIV research through the expansion of its Martin Delaney Collaboratories for HIV Cure Research program. Two key focus areas are HIV cure research in children and training the next generation of HIV researchers. Another goal is to expedite HIV cure research by bringing together scientists from many backgrounds to share data, resources and methodologies. The program is named for the late Martin Delaney, an HIV/AIDS activist and member of the National Institute of Allergy and Infectious Diseases AIDS Advisory Committee. https://bit.ly/3sngdSM

**CFAR EVENTS**

**First Wednesdays Bio-Behavioral Science Core Research-in-Development | September 1 @ 4PM.** Matthew Sullivan, Ph.D. presents, *Investigating determinants of willingness to initiate HIV pre-exposure prophylaxis (PrEP) in people with Opioid Use Disorder - CFAR Developmental Award Submission*

**HOPE Physicians Conference | The next session, yet to be announced, is scheduled for September 14!* Visit [http://www.hopeconference.net/](http://www.hopeconference.net/) for archived presentations and lecture slides

**2021 Virtual Inter-CFAR Women and HIV Symposium | Call for abstracts extended to September 3!**

**25th Annual CFAR National (Virtual) Meeting | November 1 - 5**

**PUBLICATIONS HIGHLIGHTS**

*Using electronic health records to identify candidates for human immunodeficiency virus pre-exposure prophylaxis: An application of super learning to risk prediction when the outcome is rare*

*Immune Correlates of Diffuse Myocardial Fibrosis and Diastolic Dysfunction Among Aging Women With Human Immunodeficiency Virus*

*Structural Issues Associated with Pre-exposure Prophylaxis Use in Men Who Have Sex with Men*

*Intersecting internalized stigmas and HIV self-care among men who have sex with men and who use substances*

*Design and Delivery of Real-Time Adherence Data to Men Who Have Sex with Men Using Antiretroviral Pre-exposure Prophylaxis via an Ingestible Electronic Sensor*
Competitive Revision and Administrative Supplements to Existing NICHD HIV Grants and Cooperative Agreements to Understand HIV Health Impacts of COVID-19 NOT-HD-21-037 (NICHD)

When Pandemics Collide NOT-AI-21-057; NIAID (R01, R21)

Advancing HIV/AIDS Research through Computational Neuroscience NOT-DA-21-030: NIDA (R01, R21, R03, DP2, DP1, K99/R00, K01, R36, P01, R15, K24)

Harnessing Big Data to Halt HIV NOT-AI-21-054; NIAID (R01)

HIV Drug Resistance Assays and Actionable Data Dissemination Strategies NOT-AI-21-056; NIAID (R01, R21, U01, U24, R41/R42, R43/R44)

HIV/AIDS Funding Opportunities

Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional) RFA-CA-21-056.html
Application Receipt Date(s): 12/15/21

American Women: Assessing Risk Epidemiologically (AWARE) (R01 Clinical Trial Optional) RFA-AI-21-058
Application Receipt Date(s): 12/9/21

Notice of Intent to Publish a Funding Opportunity Announcement for HIV Prevention and Alcohol (R34 Clinical Trials Optional) NOT-AA-21-036 (NIAAA)
Application Receipt Date(s): N/A

Notice of Change to Funding Opportunity for PAR-21-246, "HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)" NOT-TW-21-007 (FIC)
Application Receipt Date(s): N/A

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 - Clinical Trial Not Allowed) RFA-DA-22-033 (NIDA)
Application Receipt Date(s): 2/18/2022

Notice of Intent to Publish a Funding Opportunity Announcement for HIV Prevention and Alcohol (R01 Clinical Trials Optional) NOT-AA-21-035 (NIAAA)
Application Receipt Date(s): N/A

Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional) RFA-DA-23-001 (NIDA)
Application Reception Date(s): 8/12/22

Innate Immune Memory Impacting HIV Acquisition and/or Control (R21 Clinical Trial Not Allowed) RFA-AI-21-041 (NIAID)
Application Receipt Date(s): 12/7/21

HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) PAR-21-246 (FiC)
Application Receipt Date(s): 12/9/22

Notice of Participation of the National Institute on Aging (NIA) in PAR-21-246 "HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)" NOT-AG-21-031 (NIA)
Application Receipt Date(s): N/A

Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R01 Clinical Trial Not Allowed) RFA-DE-22-003 (NIDCR)
Application Receipt Date(s): 11/19/21

Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R21 Clinical Trial Not Allowed) RFA-DE-22-004 (NIDCR)
Application Receipt Date(s): 12/19/21

Elucidating the Effects of ART on Neuronal Function in the Context of SUD and HIV (R01 - Clinical Trials Not Allowed) RFA-DA-22-003 (NIDA)
**ACKNOWLEDGEMENTS**

This newsletter is a publication of the Harvard University Center for AIDS Research (HU CFAR), an NIH funded program (P30 AI060354) which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NIDCR, NHLBI, NIDA, NIMH, NIA, NIDDK, NINR, NIMHD, FIC, and OAR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

To learn more about core services available to the Harvard HIV research community and for information about the HU CFAR, please visit https://cfar.globalhealth.harvard.edu/

*email cfar@harvard.edu . follow @HarvardCFAR . visit https://cfar.globalhealth.harvard.edu/*